Filters: keyword is In [Clear All Filters]
- 2009
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography,
Epilepsia, vol. 50, no. 1, pp. 88-98.
Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex,
Anesthesiology, vol. 110, no. 1, pp. 95-105.
- 2008
Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model,
J Psychiatr Res, vol. 42, no. 14, pp. 1189-97.
Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy,
J Psychiatr Res, vol. 42, no. 12, pp. 1000-9.
The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments,
J Pharmacol Toxicol Methods, vol. 57, no. 2, pp. 114-30.
Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex,
Eur J Pharm Sci, vol. 33, no. 3, pp. 217-29.
Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients,
Clin Pharmacol Ther, vol. 83, no. 3, pp. 443-51.
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model,
J Pharmacol Exp Ther, vol. 324, no. 3, pp. 1234-42.
Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats,
Br J Pharmacol, vol. 153, no. 5, pp. 1072-84.
Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients,
Eur J Clin Pharmacol, vol. 64, no. 3, pp. 329-34.
Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics,
Eur J Pharm Sci, vol. 34, no. 2-3, pp. 149-63.
Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex,
Br J Pharmacol, vol. 154, no. 6, pp. 1369-78.
Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes,
Am J Obstet Gynecol, vol. 198, no. 1, pp. 108 e1-6.
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats,
Pharm Res, vol. 25, no. 1, pp. 183-93.
Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain,
Br J Pharmacol, vol. 155, no. 7, pp. 1127-38.
The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women,
Br J Clin Pharmacol, vol. 66, no. 6, pp. 866-74.
Prediction of attack frequency in migraine treatment,
Cephalalgia, vol. 28, no. 8, pp. 847-55.
Extensions to the visual predictive check to facilitate model performance evaluation,
J Pharmacokinet Pharmacodyn, vol. 35, no. 2, pp. 185-202.
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research,
Trends Pharmacol Sci, vol. 29, no. 4, pp. 186-91.
Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat,
Pharm Res, vol. 25, no. 4, pp. 792-804.
Relevance of absorption rate and lag time to the onset of action in migraine,
Clin Pharmacokinet, vol. 47, no. 2, pp. 139-46.
- 2007
Analysis of responses in migraine modelling using hidden Markov models,
Stat Med, vol. 26, no. 22, pp. 4163-78.
Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks,
Antimicrob Agents Chemother, vol. 51, no. 10, pp. 3720-5.
Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man,
Pharm Res, vol. 24, no. 11, pp. 2031-9.
Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior,
Eur J Pharm Sci, vol. 32, no. 3, pp. 200-8.



